

Ref: GLL/BSE/2021/Feb-03

Date: February 13, 2021

To  
Corporate Relations Manager  
BSE Limited  
Phiroje Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

To  
Listing Manager  
The Ahmedabad Stock Exchange Limited  
A-2, Kamdhenu Complex,  
Opposite Sahajanand College,  
120 Feet Ring Rd, Panjara Pol, Ambawadi,  
Ahmedabad – 380 015

To  
The Secretary  
The Calcutta Stock Exchange Limited  
#7, Lyons Range, Murgighata,  
Dalhousie, Kolkata – 700 001

**Sub:** Outcome of the Board Meeting held on February 13, 2021 of Gennex Laboratories Limited  
**Ref:** Regulation 33 & 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Ma'am,

In just concluded Meeting of the Board Directors of the Company, the board has considered and approved:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended December 31, 2020 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended December 31, 2020 (annexed herewith);

This intimation is also uploaded in the Company website: [www.gennexlab.com](http://www.gennexlab.com).

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours Truly,

**For Gennex Laboratories Limited**



**Rajesh Vankadara**  
Company Secretary &  
Compliance Officer  
Membership #A44949



**Encl:** As above


**Gennex Laboratories Limited**

**Independent Auditor's Limited Review Report on Standalone Unaudited Quarterly and Year to Date Results Financial Results of Gennex Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended**

To  
**The Board of Directors,  
GENNEX LABORATORIES LIMITED  
Hyderabad**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Gennex Laboratories Limited** for the quarter ended **December, 2020**, and the year to date results for the period April 01, 2020 to December 31, 2020, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. The statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement, insofar as it relates to the amounts and disclosures for the quarter ended **December, 2020**, and the year to date results for the period April 01, 2020 to December 31, 2020, in accordance with the Standard on Review Engagements (SRE) 2410 on "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review if substantially less in scope than an audit conducted in accordance with Standard on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) specified under Section 133 of the Companies Act, 2013 as amended read with rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For PPKG & Co.**  
Chartered Accountants  
Firm Registration Number.009655S

  
**CA Giridhari Lal Foshniwal**  
(Partner)  
Membership No. 205140  
**UDIN: 21205140AAAAER9038**



**Place:** Hyderabad  
**Date:** 13<sup>th</sup> February, 2021



GENNEX LABORATORIES LIMITED

REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, SANGAREDDY DIST - 502 325

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2020

Tel. No. +91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

CIN: L24230TG1990PLC011168

PART - I							
Statement of standalone Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2020							
(Rs. in lakhs)							
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>Income from Operations</b>						
	(a) Revenue from Operations	1545.36	1493.77	1468.08	4343.76	4416.41	5561.73
	(b) Other operating Income	16.05	19.40	22.66	50.22	77.08	95.14
	<b>Total Income from operations (net)</b>	<b>1561.41</b>	<b>1513.17</b>	<b>1490.74</b>	<b>4393.98</b>	<b>4493.49</b>	<b>5656.87</b>
2	<b>Expenses</b>						
	(a) Cost of material consumed	987.32	908.80	912.07	2548.63	2774.47	3513.11
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-76.86	-19.83	-10.17	100.05	-169.74	-151.11
	(d) Employee benefit expense	192.07	168.73	193.19	515.90	526.53	681.19
	(f) Finance Cost	14.09	22.78	16.91	52.89	59.98	75.36
	(g) Depreciation and amortisation expense	22.07	21.97	30.51	66.02	81.47	100.50
	(h) Other expenses	267.07	288.66	314.36	781.74	1016.23	1193.82
	<b>Total expenses</b>	<b>1405.76</b>	<b>1391.11</b>	<b>1456.87</b>	<b>4065.23</b>	<b>4288.94</b>	<b>5412.87</b>
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	155.65	122.06	33.87	328.75	204.55	244.00
4	Exceptional items	0.00	0.00	0	0.00	10.86	10.86
5	Profit(+)/Loss(-) before tax (3+4)	155.65	122.06	33.87	328.75	215.41	254.86
6	Taxes of earlier years	0.00	0.00	0.00	0.00	0.00	-10.34
7	Current Tax	-33.04	-35.50	-14.00	-82.74	-60.00	-75.00
8	Deferred tax(benefit/expense)						16.12
9	Total Tax expense	-33.04	-35.50	-14.00	-82.74	-60.00	-69.22
10	Net movement in regulatory deferral account balances related to Profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) for the period from continuing operation (5-9)	122.61	86.56	19.87	246.01	155.41	185.64
12	Profit(+)/Loss(-) from discontinued operations before tax						
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	Net Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
16	Total profit(loss) for period	122.61	86.56	19.87	246.01	155.41	185.64
17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	0




18	Net profit(loss) for period	122.61	86.56	19.87	246.01	155.41	185.64
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03
	Other Equity						2320.38
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) ( of Rs. 1 each ) (not annualised) :						
	(a) Basic	0.097	0.068	0.016	0.194	0.123	0.147
	(b) Diluted	0.097	0.068	0.016	0.194	0.123	0.147

**Notes to the results:**

- 1) The above unaudited standalone financial results have been reviewed by the Audit Committee of its meeting held on feb 13, 2021 and the same were approved and
- 2) The statutory Auditors of the Company have carried out the limited review of the above unaudited financial result for the quarter ended December 31,2020.
- 3) The above results have been prepared in accordance with Companies ( Indian Accounting Standard) Rules, 2015 (IndAS) prescribed under section 133 of the accounting practices and policies to the extent applicable Companies Act, 2013 and other recognised.
- 4) The company operates in single segment and therefore the sgament reporting as per AS-17 is not applicable for the Company.
- 5) Previous periods figures have been rearranged / regrouped wherever necessary.
- 6) The quarterly unaudited financial result for the quarter ended December 31 2020 are available on the Company's website i.e., [www.gennexlab.com](http://www.gennexlab.com) and also available

Place: Hyderabad

Date: 13.02.2021

  
For and on behalf of the Board  
For Gennex Laboratories Limited  
sd/-  
T M GOPALAKRISHNAN  
Whole Time Director



**Independent Auditor's Review Report on Consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
**The Board of Directors,  
GENNEX LABORATORIES LIMITED  
Hyderabad**

1. We have reviewed the accompanying Statement of unaudited Consolidated Financial Results of **Gennex Laboratories Limited** ("the Parent") and its Associates (referred to as "the Group") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates for the quarter ended **December, 2020**, and the year to date results for the period April 01, 2020 to December 31, 2020 ("the Statement"), being submitted by the company along with its Associate, pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended **December, 2020**, and the year to date results for the period April 01, 2020 to December 31, 2020, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Management and approved by the Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended ("Ind AS"), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

**Deccan Remedies Limited;**


Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Associate, which have been reviewed by their auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs. 0.00 lakhs, total net Profit after tax of Rs. 0.00 lakhs and total comprehensive Profit of Rs. 0.00 lakhs, for the quarter ended **December, 2020**, and the year to date results for the period April 01, 2020 to December 31, 2020 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management
6. Our conclusion, in so far as it relates to the balances and affairs of the Associate is based on the review report of other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us. Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

**Place:** Hyderabad  
**Date:** 13<sup>th</sup> February, 2021

**For PPKG & Co.**  
Chartered Accountants  
Firm Registration Number.009655S

  
**CA Giridhari Lal Toshniwal**  
(Partner)  
Membership No. 205140  
UDIN: 21205140AAAAES4207





GENNEX LABORATORIES LIMITED

REGD. OFF: SURVEY NO. 133, BOLLARAM, JINNARAM MANDAL, SANGAREDDY DIST - 502 325

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED 31ST DECEMBER, 2020

Tel. No. +91-40-67334400-30, Fax: +91-40-67334433, Email: info@gennexlab.com website: www.gennexlab.com

CIN: L24230TG1990PLC011168


PART - I							
Statement of Consolidated Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2020							
(Rs. in lakhs)							
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations						
	(a) Revenue from Operations	1545.36	1493.77	1468.08	4343.76	4416.41	5561.73
	(b) Other operating Income	16.05	19.40	22.66	50.22	77.08	95.14
	Total Income from operations (net)	1561.41	1513.17	1490.74	4393.98	4493.49	5656.87
2	Expenses						
	(a) Cost of material consumed	987.32	908.80	912.07	2548.63	2774.47	3513.11
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-76.86	-19.83	-10.17	100.05	-169.74	-151.11
	(d) Employee benefit expense	192.07	168.73	193.19	515.90	526.53	681.19
	(f) Finance Cost	14.09	22.78	16.91	52.89	59.98	75.36
	(g) Depreciation and amortisation expense	22.07	21.97	30.51	66.02	81.47	100.50
	(h) Other expenses	267.07	288.66	314.36	781.74	1016.23	1193.82
	Total expenses	1405.76	1391.11	1456.87	4065.23	4288.94	5412.87
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	155.65	122.06	33.87	328.75	204.55	244.00
4	Exceptional items	0.00	0.00	0	0.00	10.86	10.86
5	Profit(+)/Loss(-) before tax (3+4)	155.65	122.06	33.87	328.75	215.41	254.86
6	Taxes of earlier years	0.00	0.00	0.00	0.00	0.00	-10.34
7	Current Tax	-33.04	-35.50	-14.00	-82.74	-60.00	-75.00
8	Deferred tax(benefit/expense)						16.12
9	Total Tax expense	-33.04	-35.50	-14.00	-82.74	-60.00	-69.22
10	Net movement in regulatory deferral account balances related to Profit or loss and the related deferred tax movement	0.00	0.00	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) for the period from continuing operation (5-9)	122.61	86.56	19.87	246.01	155.41	185.64
12	Profit(+)/Loss(-) from discontinued operations before tax						
13	Tax expense of discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
14	Net Profit(loss) for the period from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	0.0	0.0	0.0	0.0	0.0	0.0
16	Total profit(loss) for period	122.61	86.56	19.87	246.01	155.41	185.64



17	Other comprehensive Income net of taxes	0.00	0.00	0.00	0.00	0.00	0
18	Net profit(loss) for period	122.61	86.56	19.87	246.01	155.41	185.64
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1265.03	1265.03	1265.03	1265.03	1265.03	1265.03
	Other Equity						2320.38
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) ( of Rs. 1 each ) (not annualised) :						
	(a) Basic	0.097	0.068	0.016	0.194	0.123	0.147
	(b) Diluted	0.097	0.068	0.016	0.194	0.123	0.147

**Notes to the results:**

- 1) The above unaudited standalone financial results have been reviewed by the Audit Committee of its meeting held on feb 13, 2021 and the same were approved and
- 2) The statutory Auditors of the Company have carried out the limited review of the above unaudited financial result for the quarter ended December 31,2020.
- 3) The above results have been prepared in accordance with Companies ( Indian Accounting Standard) Rules, 2015 (IndAS) prescribed under section 133 of the accounting practices and policies to the extent applicable Companies Act, 2013 and other recognised.
- 4) The company operates in single segment and therefore the sgament reporting as per AS-17 is not applicable for the Company.
- 5) Previous periods figures have been rearranged / regrouped wherever necessary.
- 6) The quarterly unaudited financial result for the quarter ended December 31 2020 are available on the Company's website i.e., [www.gennexlab.com](http://www.gennexlab.com) and also available

  
  
 For and on behalf of the Board  
 For Gennex Laboratories Limited  
 sd/-  
**T M GOPALAKRISHNAN**  
 Whole Time Director

Place: Hyderabad  
 Date: 13.02.2021